Previous 10 | Next 10 |
2023-12-26 08:19:44 ET More on BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript BrainStorm, FDA to discuss regulatory path forward for ALS therapy Brainstorm realigns resources to support NurOwn development ...
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments PR Newswire NEW YORK , Dec. 26, 2023 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for n...
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS PR Newswire Meeting Provided a Clear Path for Planned Phase 3b Trial NEW YORK , Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a le...
2023-11-20 10:57:50 ET More on BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS PR Newswire Meeting will take place on December 6 ; Company plans to seek Special Protocol Assessment (SPA) NEW YORK , Nov....
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia PR Newswire Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes NEW YORK , Nov. 17, 2023 /PRNewswire...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...
2023-11-14 12:20:09 ET Start Time: 08:30 End Time: 08:58 BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Chaim Lebovits - President and CEO Stacy Lindborg - Co-CEO Alla Patlis -...
2023-11-14 07:07:42 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn development Brainstorm to pull marketing application for ALS therapy ...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn PR Newswire The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, see...
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Company received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn® C...
A look at the top 10 most actives in the United States Tilray Brands Inc. (TLRY) rose 39.5% to $2.47 on volume of 149,005,559 shares Tesla Inc. (TSLA) fell 5.6% to $183.28 on volume of 125,934,900 shares PROSHARES TRUST (SQQQ) rose 5.7% to $11.95 on volume of 124,394,426 shares Jaguar H...